Skip to main content

Table 2 Univariate and multivariable analyses for OS

From: Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer

Characteristics

Univariate analysis

Multivariable analysis

HR (95% CI)

p value

HR (95% CI)

p value

Age

    

 (< 65 yr vs. ≥ 65 yr)

1.13 (0.66–1.92)

0.660

–

0.171

Gender

    

 (Male vs. Female)

1.22 (0.65–2.28)

0.542

–

0.961

ECOG PS

    

 (0–1 vs. ≥ 2)

0.43 (0.13–1.41)

0.166

–

0.198

Smoking history

    

 (Yes vs. No)

1.27 (0.73–2.23)

0.385

–

0.593

Weight loss

    

 (Yes vs. No)

0.66 (0.30–1.47)

0.308

–

0.215

Baseline brain metastases

    

 (Yes vs. No)

0.95 (0.53–1.72)

0.873

–

0.317

Baseline liver metastases

    

 (Yes vs. No)

3.01 (1.75–5.20)

 < 0.001

2.58 (1.45–4.58)

0.001

Baseline bone metastases

    

 (Yes vs. No)

1.81 (1.05–3.11)

0.032

–

0.069

Number of metastases

    

 (< 3 vs. ≥ 3)

2.39 (1.38–4.14)

0.002

1.86 (1.04–3.32)

0.036

Immunotherapy regimens

    

 (Durvalumab vs. Atezolizumab)

1.29 (0.77–2.17)

0.333

–

0.149

Cycles of immunotherapy

    

 (< 6 vs. ≥ 6)

0.75 (0.44–1.28)

0.287

–

0.424

PCI

    

 (Yes vs. No)

0.67 (0.29–1.57)

0.460

–

0.944

  1. OS, overall survival; HR, hazard ratio; CI, confidence interval; yr, years; ECOG PS, Eastern Cooperative Oncology Group performance status; PCI, prophylactic cranial irradiation
  2. The p values of the bold were ≤ 0.05, which were considered statistically significant and were used for subsequent prognostic analysis
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us